Metagenomi (MGX) News Today

Metagenomi, Inc. (NASDAQ:MGX) shares moved higher amid fresh analyst commentary. HC Wainwright not only reaffirmed its “Buy” rating but also trimmed expected losses across multiple quarters and fiscal years. Offsetting some of that enthusiasm, Chardan Capital widened its loss estimates for FY2025 and FY2026, though it too maintains a Buy rating.

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating on MGX with a $7.00 price target.Metagenomi's (MGX) "Buy" Rating Reaffirmed at HC Wainwright
• Positive Sentiment: HC Wainwright lifted EPS forecasts across eight periods, reducing projected losses to:
  • Q3 2025: –$0.52 vs. –$0.57
  • Q4 2025: –$0.56 vs. –$0.62
  • FY 2025: –$2.29 vs. –$2.41
  • Q1 2026: –$0.61 vs. –$0.66
  • Q2 2026: –$0.64 vs. –$0.71
  • Q3 2026: –$0.66 vs. –$0.75
  • Q4 2026: –$0.69 vs. –$0.79
  • FY 2026: –$2.60 vs. –$2.91
  All forecasts come with a Buy rating and $7.00 target.
• Negative Sentiment: Chardan Capital lowered its loss forecasts, widening expected losses to –$2.34 for FY 2025 (from –$1.44) and to –$1.20 for FY 2026 (from –$0.66), though it retains a Buy rating with an $11.00 target.